Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT03756103
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT03756103
-
- Other papers using this trial's data
- A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03756103. Randomized; double masking; primary purpose treatment. Start 2019-01-11 (actual); primary completion 2020-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
- Condition
- Hypertension,Essential
- Intervention (Drug)
- SPH3127 tablet Dose 1
- Intervention (Drug)
- SPH3127 tablet Dose 2
- Intervention (Drug)
- SPH3127 tablet Dose 3
- Intervention (Drug)
- SPH3127 tablet Placebo
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Collaborator
- R&G Pharma Studies Co.,Ltd.
Record details
- Record id
cardio:ct-nct03756103- Content hash
5400958f55f9ebcebe981c599396f1ebef44926a46141a6826b85efe9d8a8436